首页> Molecular carcinogenesis> LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

导出原文传递

翻译打印收藏纠错

第一作者： Guangxin,Ma

第一单位： Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.;Hematology and Oncology Unit, Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, Shandong, China.

作者： Guangxin,Ma ^[1] ; Deniz,Gezer ^[2] ; Oliver,Herrmann ^[2] ; Kristina,Feldberg ^[2] ; Mirle,Schemionek ^[2] ; Mohamad,Jawhar ^[3] ; Andreas,Reiter ^[3] ; Tim H,Brümmendorf ^[2] ; Steffen,Koschmieder ^[2] ; Nicolas,Chatain ^[2]

作者单位： Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.;Hematology and Oncology Unit, Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, Shandong, China. ^[1] Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. ^[2] Department of Hematology and Oncology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany. ^[3]

关键词 LCP1 differentiation block hypereosinophilia mTORC2 myeloid neoplasms